Sai Life Sciences Limited, a Hyderabad-based Contract Research, Development, and Manufacturing Organization (CRDMO), has announced its financial results for the fiscal year ended March 31, 2025. The company reported a significant 105% year-on-year increase in net profit, reaching ₹170 crore, up from ₹83 crore in FY24.

The company's revenue from operations grew by 16%, totaling ₹1,695 crore in FY25 compared to ₹1,465 crore in the previous fiscal year. This growth reflects the company's robust performance in the CRDMO sector, catering to both global pharmaceutical and biotech clients.

Q4FY25 Performance Highlights

In the fourth quarter of FY25, Sai Life Sciences reported a 32% increase in revenue, amounting to ₹580 crore, compared to ₹439 crore in Q4FY24. The Profit After Tax (PAT) for the quarter rose by 57%, reaching ₹88 crore from ₹56 crore in the same period last year.

The company's Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹161 crore for Q4FY25, marking a 30% increase from ₹124 crore in Q4FY24. The EBITDA margin remained strong at 28%, indicating efficient operational management.

Strategic Initiatives and Investments

During FY25, Sai Life Sciences made significant strides in expanding its capabilities. The company launched a Peptide Research Centre to meet the growing demand for complex peptide synthesis and conjugation, enhancing its service offerings in next-generation therapeutics.

Additionally, the company completed a planned ₹720 crore debt repayment, significantly strengthening its balance sheet and reducing interest costs. The capital expenditure for the year stood at ₹408 crore, focusing on enhancing manufacturing infrastructure and expanding discovery capabilities.

Leadership Commentary

Mr. Krishna Kanumuri, Managing Director and CEO of Sai Life Sciences, expressed satisfaction with the company's performance, attributing the success to solid execution, capacity expansion, and deeper customer engagement. He emphasized the company's commitment to delivering seamless solutions across the drug development lifecycle.

Mr. Siva Chittor, Director and Chief Financial Officer, highlighted the company's consistent momentum across its CDMO and CRO segments. He noted that the company's EBITDA margin expanded to 25% in FY25, aligning with growth aspirations, and that the debt repayment has significantly strengthened the balance sheet.

Future Outlook

With India emerging as a strategic hub in global drug development, Sai Life Sciences is well-positioned to tap into new growth opportunities. The company remains focused on investing in technology, infrastructure, and talent to stay aligned with the evolving needs of its clients.

As Sai Life Sciences steps into FY26, its priorities include expanding capabilities, improving execution, and delivering lasting value to stakeholders. The company's strong financial performance in FY25 sets a solid foundation for continued growth and success in the coming years.

The Upcoming IPOs in this week and coming weeks are Integrity Borana Weaves, Belrise Industries, Wagons Learning.

The Current active IPO are Accretion Pharmaceuticals, Integrity Infrabuild Developers and Virtual Galaxy Infotech.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.